Regolieva 40mg Tablet: Multi-Kinase Inhibition for Refractory Colorectal, GIST, and Hepatic Malignancies Are you searching for a reliable Regolieva 40mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced multi-kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Regolieva 40mg? Regolieva 40mg is an oral targeted therapy containing the active pharmaceutical ingredient Regorafenib. Manufactured by Allieva Pharma Pvt Ltd, this 40mg tablet is a potent multi-kinase inhibitor designed to attack cancer on multiple fronts. It is primarily utilized as a salvage therapy for patients with advanced cancers that have progressed despite standard treatments, providing a vital line of defense in complex oncology cases. 1. Therapeutic Indications Metastatic Colorectal Cancer (mCRC): For patients previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Gastrointestinal Stromal Tumors (GIST): For patients with locally advanced, unresectable, or metastatic GIST who were previously treated with imatinib mesylate and sunitinib malate. Hepatocellular Carcinoma (HCC): For patients with liver cancer who have been previously treated with sorafenib. 2. Mechanism of Action: Triple-Action Multi-Kinase Inhibition Anti-Angiogenesis: It inhibits VEGFR1, VEGFR2, and VEGFR3, effectively “starving“ the tumor by blocking the growth of new blood vessels. Oncogenesis Inhibition: It targets various kinases (like KIT, RET, and RAF-1) that drive the uncontrolled growth and proliferation of cancer cells. Tumor Microenvironment Regulation: By inhibiting PDGFR and FGFR, it disrupts the signaling between the tumor and its surrounding tissue, slowing down the spread and invasion of malignant cells. 3. Administration and Dosage Management Standard Dosing: The typical dose is 160mg (four 40mg tablets) taken once daily for the first 21 days of each 28-day cycle. Administration: Must be taken after a low-fat meal (containing less than 30% fat) to ensure consistent absorption. Consistency: Tablets must be swallowed whole with water. Do not crush or chew. It should be taken at the same time each day. Clinical Side Effects & Safety Monitoring Hepatotoxicity: Potential for severe drug-induced liver injury; Liver Function Tests (LFTs) are mandatory before and during treatment. Hand-Foot Skin Reaction (HFSR): Redness, pain, or swelling on the palms and soles is common; proactive dermatological care is recommended. Hypertension: Blood pressure often increases early in the cycle and must be monitored weekly. Gastrointestinal Health: Monitoring for severe diarrhea, nausea, and weight loss. Bleeding Risks: Due to its anti-angiogenic properties, patients should be monitored for internal or external bleeding events. Why Source Regolieva 40mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Regolieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us